Petros Pharmaceuticals, Inc. (PTPI) shareholders
Close on Oct 19, 2026Market cap $135.07KP/E –Yield –
Ownership
Who owns Petros Pharmaceuticals's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Iroquois Capital Management, LLC Joint filing with Richard Abbe (9.99%), Kimberly Page (9.99%) | 5,939,954 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Richard Abbe Joint filing with Iroquois Capital Management, LLC (9.99%), Kimberly Page (9.99%) | 4,434,773 | 9.99% | 13G (passive) amendment | Dec 21, 2025 |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B Joint filing with Ayrton Capital LLC (6.20%), Waqas Khatri (6.20%) | 657,614 | 6.20% | 13G (passive) amendment | Dec 31, 2024 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Weinstein | Chief Accounting Officer | 636,004 | 1.50% | Jun 25, 2026 |
| Fady Boctor | See Remarks | 894,986 | 2.11% | Jun 5, 2026 |
| Mitchell Arnold | See Remarks | 150,390 | 0.35% | Feb 21, 2025 |
| Wayne Remell Walker | Director | 881,333 | 2.08% | Jun 8, 2026 |
| Joshua Silverman | Director | 8,790,450 | 20.75% | Jun 5, 2026 |
| Bruce Bernstein | Director | 3,762,334 | 8.88% | Jun 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Wayne Remell Walker Director | Jun 5, 2026 | Award | +375,000 | – | – | 881,333 |
| Bruce Bernstein Director | Jun 5, 2026 | Award | +1,875,000 | – | – | 3,762,334 |
| Fady Boctor See Remarks | Jun 5, 2026 | Award | +375,000 | – | – | 894,986 |
| Joshua Silverman Director | Jun 5, 2026 | Award | +4,375,000 | – | – | 8,790,450 |
| Fady Boctor See Remarks | Jan 2, 2026 | Award | +500,000 | – | – | 519,986 |
| Joshua Silverman Director | Jan 2, 2026 | Award | +4,375,000 | – | – | 4,415,450 |
| Wayne Remell Walker Director | Jan 2, 2026 | Award | +500,000 | – | – | 506,333 |
| Bruce Bernstein Director | Jan 2, 2026 | Award | +1,875,000 | – | – | 1,887,334 |
| Mitchell Arnold See Remarks | Feb 19, 2025 | Award | +150,000 | – | – | 150,000 |
| Fady Boctor See Remarks | Feb 19, 2025 | Award | +450,000 | – | – | 499,645 |
| Wayne Remell Walker Director | Feb 19, 2025 | Award | +150,000 | – | – | 158,314 |
| Joshua Silverman Director | Feb 19, 2025 | Award | +1,000,000 | – | – | 1,011,237 |
| Bruce Bernstein Director | Feb 19, 2025 | Award | +300,000 | – | – | 308,346 |
| Fady Boctor See Remarks | Dec 21, 2023 | Award | +49,645 | – | – | 49,645 |
| Bruce Bernstein Director | Apr 26, 2023 | Option exercise | +6,050 | – | – | 8,346 |
| Wayne Remell Walker Director | Apr 26, 2023 | Option exercise | +6,050 | – | – | 8,314 |
| Joshua Silverman Director | Apr 26, 2023 | Option exercise | +6,722 | – | – | 11,237 |
| Greg Bradley Director | Apr 26, 2023 | Option exercise | +6,050 | – | – | 8,314 |
| Wayne Remell Walker Director | Jan 20, 2023 | Option exercise | +2,264 | – | – | 2,264 |
| Bruce Bernstein Director | Jan 20, 2023 | Option exercise | +2,264 | – | – | 2,296 |
| Joshua Silverman Director | Jan 20, 2023 | Option exercise | +2,515 | – | – | 4,515 |
| Greg Bradley Director | Jan 20, 2023 | Option exercise | +2,264 | – | – | 2,264 |
| Juggernaut Partners III GP, L.P. 10% owner | Dec 22, 2021 | Buy | +145,773 | $3.43 | $500.00K | 5,703,544 |
| Juggernaut Partners III GP, Ltd. 10% owner | Nov 29, 2021 | Buy | +500,000 | $3.00 | $1.50M | 5,557,771 |
| John D. Shulman Director, 10% owner | Oct 18, 2021 | Buy | +1,661,807 | $1.72 | $2.86M | 5,057,771 |
| Juggernaut Partners III GP, L.P. 10% owner | Dec 1, 2020 | Award | +3,395,964 | – | – | 3,395,964 |
| Keith Lavan Chief Financial Officer | Dec 1, 2020 | Award | +975 | – | – | 975 |
| Andrew Gesek President, Timm Medical | Dec 1, 2020 | Award | +97 | – | – | 97 |
| John D. Shulman Director, 10% owner | Dec 1, 2020 | Award | +3,382,416 | – | – | 3,382,416 |
| Joshua Silverman Director | Dec 1, 2020 | Award | +20,000 | – | – | 20,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Petros Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2 shares on Sep 17, 2026 over the last 90 days.
See a number that looks wrong?